<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258258</url>
  </required_header>
  <id_info>
    <org_study_id>I 38504</org_study_id>
    <secondary_id>RPCI-I-38504</secondary_id>
    <secondary_id>NOVARTIS-RPCI-I-38504</secondary_id>
    <secondary_id>ABBOTT-RPCI-I-38504</secondary_id>
    <nct_id>NCT00258258</nct_id>
  </id_info>
  <brief_title>Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders</brief_title>
  <official_title>An Open Label Dose Escalation Study of Intravenous Paricalcitol (ZEMPLAR™) [19-NOR-1 ALPHA, 25 - (OH)D] With Zoledronic Acid (Zometa™) in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Paricalcitol may cause multiple myeloma cells to look more like normal cells, and&#xD;
      to grow and spread more slowly. Paricalcitol may also stop the growth of the cancer cells by&#xD;
      blocking blood flow to the cancer. Zoledronate may delay or prevent bone metastases in&#xD;
      patients with multiple myeloma. Giving paricalcitol together with zoledronate may be an&#xD;
      effective treatment for multiple myeloma or other plasma cell disorders.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the side effects and best dose of paricalcitol when&#xD;
      given with zoledronate in treating patients with relapsed or refractory multiple myeloma or&#xD;
      other plasma cell disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of paricalcitol when used with zoledronate in&#xD;
           patients with relapsed or refractory multiple myeloma or other plasma cell disorders.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the antimyeloma activity of paricalcitol in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of paricalcitol.&#xD;
&#xD;
      Patients receive paricalcitol IV over 15 minutes on days 1, 8, and 15 and zoledronate IV over&#xD;
      15 minutes on day 22. Treatment repeats every 28 days in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of paricalcitol until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn due to low accrual&#xD;
  </why_stopped>
  <start_date>August 2005</start_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">7</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paricalcitol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of relapsed or refractory multiple myeloma (MM) or other plasma cell&#xD;
             disorder (PCD)&#xD;
&#xD;
               -  At least one previous treatment for MM or PCD required&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Calcium ≤ 10.5 mg/dL&#xD;
&#xD;
          -  No renal stone formation within the past 5 years for patients who have had curative&#xD;
             therapy for a condition associated with the risk of stones (e.g., hyperparathyroidism,&#xD;
             bladder dysfunction, obstructive uropathy) OR had a single episode of confirmed&#xD;
             urolithiasis&#xD;
&#xD;
          -  No calculi in urinary tract confirmed by renal ultrasonography, kidney, ureter, and&#xD;
             bladder (KUB) x-ray, or other imaging modality&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during study and for 3 months after&#xD;
             study completion&#xD;
&#xD;
          -  No osteonecrosis of the jaw&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biological composition of calcitriol, paricalcitol, or zoledronate&#xD;
&#xD;
          -  No uncontrolled intercurrent illness that would preclude study compliance&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that may preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine&#xD;
&#xD;
          -  More than 4 weeks since prior high-dose steroids&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents or therapies for multiple myeloma or plasma&#xD;
             cell disorders&#xD;
&#xD;
          -  No concurrent digoxin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asher A. Chanan-Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

